货号（Catalog No.）

ATAD00281

通用名INN

Alirocumab

纯度(Purity)

>95%

浓度( Concentration)

1mg/ml

Formulation

PBS buffer pH7.5

Source

CHO cells

内毒素(Endotoxin level)

Please contact with the lab for this information.

生物活性

产品描述(Description)

Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in a.dults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.

别名(Alternative names)

REGN727,SAR-236553

靶点;物种(Specificity target name;species)

PCSK9[Homo sapiens]

种类(Species)

Homo sapiens

受体鉴定(Receptor identification)

IgG1-kappa

化学信息

分子量(MV)

146000.0 Da

CAS

1245916-14-6

存储条件(Storage)

store at -80°C

Note
For research use only. Not suitable for clinical or therapeutic use.